1. Introduction {#sec1-jcm-09-01959}
===============

Coronaviruses, enveloped viruses with a positive-sense single-stranded RNA genome, comprise the family Coronaviridae, order Nidovirales and are widely distributed in birds, humans, and other mammals \[[@B1-jcm-09-01959]\]. The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection emerged in Wuhan, Hubei, China, on 8 December 2019 \[[@B2-jcm-09-01959],[@B3-jcm-09-01959],[@B4-jcm-09-01959]\]. The outbreak has spread worldwide, and the number of confirmed cases is growing rapidly \[[@B5-jcm-09-01959]\].

Most COVID-19 patients have mild symptoms, such as fever and cough \[[@B5-jcm-09-01959]\], and have a favorable prognosis without specific treatment \[[@B4-jcm-09-01959],[@B6-jcm-09-01959],[@B7-jcm-09-01959]\]. In severe cases, dyspnea and hypoxia may develop within one week after onset of the disease and may rapidly progress to acute respiratory distress syndrome (ARDS), acute respiratory failure, septic shock, metabolic acidosis, and coagulopathy \[[@B8-jcm-09-01959]\].

The first case of COVID-19 in South Korea was a resident of Wuhan, China, who entered Incheon Airport on 19 January 2020 \[[@B9-jcm-09-01959]\]. On 17 February, the 31st COVID-19 patient was confirmed to have participated in religious ceremonies in Daegu city. Subsequently, multiple COVID-19 outbreaks occurred in South Korea, including community-associated outbreaks in Daegu city and healthcare-associated outbreaks in Cheongdo, Gyeongsangbuk-do province \[[@B10-jcm-09-01959]\].

A rapid increase in number of patients with COVID-19 can overwhelm the available medical resources, including intensive care units, negative pressure beds, and medical staff. Therefore, early assessment of risk factors for disease progression and patient prognosis is critical to ensure that patients whose disease is more likely to increase in severity can receive proper treatment in a timely manner. Thus, the Korea Centers for Disease Control and Prevention (KCDC) have established a system to triage patients in public health centers, whereby mild cases are transferred to living treatment centers, mild to moderate cases to dedicated cohort hospitals, and severe cases to tertiary university hospitals \[[@B11-jcm-09-01959]\]. Large-scale diagnostic testing was performed to find hidden COVID-19 cases in sub-populations that had a history of contact with confirmed cases. Through these processes, South Korean patients with asymptomatic infection or early symptoms of disease were identified, and early monitoring and treatment of patients with COVID-19 were conducted.

Although many published studies have summarized the clinical features of COVID-19 patients \[[@B4-jcm-09-01959],[@B6-jcm-09-01959],[@B7-jcm-09-01959],[@B12-jcm-09-01959],[@B13-jcm-09-01959],[@B14-jcm-09-01959],[@B15-jcm-09-01959]\], few have addressed the course of the disease in the early stages of symptom onset. Therefore, the clinical characteristics, imaging features, and treatment outcomes of COVID-19 patients before or immediately after onset of symptoms were investigated, with a particular focus on mild to moderate cases. We aimed to evaluate risk factors and KCDC classification models to predict disease progression in patients with early-stage COVID-19.

2. Methods {#sec2-jcm-09-01959}
==========

2.1. Study Participants {#sec2dot1-jcm-09-01959}
-----------------------

All consecutive patients with confirmed COVID-19 admitted to the Armed Forces Daegu Hospital, Daegu, South Korea, from 5 March 2020 to 18 March 2020, were enrolled in this study. According to the arrangement established by the government, the hospital was designated as a COVID-19-dedicated, 300-bed cohort hospital. The final follow-up date for this study was April 4, 2020. A total of 293 adult patients from Daegu city was admitted to the hospital during the study period. All cases were confirmed as COVID-19 using a real-time reverse transcription polymerase chain reaction (RT-PCR) (Seegene Inc., Seoul, South Korea, <https://www.seegene.com>) assay of nasal and oropharyngeal swabs \[[@B4-jcm-09-01959]\]. This retrospective cohort study was approved by the Institutional Review Board of the Korean Military Medical Association (Seongnam-si, Gyeonggi-do, South Korea) (AFMC-20015-IRB-20-015).

The following clinical data were collected using electronic medical records: age at diagnosis, sex, signs and symptoms, date of symptom onset, date of hospital admission, date of discharge or transfer, Charlson comorbidity index \[[@B16-jcm-09-01959]\], Eastern Cooperative Oncology Group (ECOG) performance status \[[@B17-jcm-09-01959]\], Multilobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension and Age (MuLBSTA) score \[[@B18-jcm-09-01959]\], pneumonia severity index \[[@B19-jcm-09-01959]\], Confusion, Urea, Respiratory rate, Blood pressure plus age ≥ 65 years (CURB-65) \[[@B20-jcm-09-01959]\], respiratory support, and treatment agents administered before and during hospitalization. We also obtained radiologic findings. Baseline non-contrast-enhanced chest computed tomography (CT) was completed for all patients to assess disease severity. To ensure the safety of medical staff by minimizing contact with patients, routine laboratory tests were not conducted in all patients but only for patients requiring clinical decisions.

2.2. Definitions {#sec2dot2-jcm-09-01959}
----------------

The triage algorithm and classification criteria according to the COVID-19 response guidelines (version 7) developed by KCDC are presented in [Figure 1](#jcm-09-01959-f001){ref-type="fig"}. The criteria address the patient's mental state, age, history of underlying comorbidities, history of smoking, respiratory symptoms, and body temperature (BT). The "KCDC Classification I" was applied if the patient's blood pressure (BP), pulse rate (PR), and respiratory rate (RR) could not be measured, and "KCDC Classification II" was applied if these parameters could be measured; thereafter, patients with COVID-19 were classified into one of four groups (Class I to IV).

In previous studies of COVID-19 patients \[[@B8-jcm-09-01959],[@B12-jcm-09-01959]\], "mild cases" were defined as patients who experienced mild symptoms, with no manifestations of pneumonia on chest imaging. "Moderate cases" referred to patients with uncontrolled fever despite administration of antipyretics and/or respiratory symptoms. Severe cases of COVID-19 were defined as patients with any of the following: respiratory distress, RR ≥ 30 breaths/min; mean oxygen saturation ≤ 93% at rest; arterial oxygen partial pressure/inspired oxygen fraction ≤ 300 mm Hg.

To quantify opacifications on pulmonary images, we applied the "CT score" as proposed in previous reports \[[@B21-jcm-09-01959],[@B22-jcm-09-01959],[@B23-jcm-09-01959]\]. In brief, each pulmonary lobe was scored as 0 (none), 1 (diameter \<1 cm), 2 (diameter 1 to 3 cm), 3 (diameter 3 cm to \<50% of the lobe), or 4 (50% to 100% of the lobe) depending on lesion size and abnormal area. The overall score was calculated by summing all five lobar scores.

2.3. Outcomes {#sec2dot3-jcm-09-01959}
-------------

Depending on the course of the disease during hospitalization, patients were classified into either the progression or improvement/stabilization group. The progression group comprised mild or moderate cases that progressed to moderate or severe cases, while the improvement/stabilization group comprised mild cases that did not progress further. Progression-free survival (PFS) was defined as the duration of time over which patients with COVID-19 remained stable during their hospitalization.

2.4. Propensity Score (PS)-Matched Analyses {#sec2dot4-jcm-09-01959}
-------------------------------------------

To adjust the outcomes of patients with COVID-19 for potential confounding factors, we conducted a PS-matched case-control study. We selected 10 variables for adjustment using univariable analyses ([Table A1](#jcm-09-01959-t0A1){ref-type="table"}): age, healthcare-associated infection, ECOG performance status, asymptomatic on initial evaluation, BT at hospital admission, diastolic BP at hospital admission, PR at hospital admission, SpO~2~ at hospital admission, hypertension, and diabetes mellitus \[[@B24-jcm-09-01959],[@B25-jcm-09-01959]\]. We then performed PS-matched analyses by attempting to match cases and control patients (1:1 matching) using the nearest-neighbor-matching method. A match occurred when the difference in the logits of the PS was \<0.2 times the standard deviation (SD) of the scores.

2.5. Statistical Analysis {#sec2dot5-jcm-09-01959}
-------------------------

We assessed all variables using the Shapiro--Wilk test to evaluate Gaussian distributions. Descriptive statistics are presented as median and interquartile range (IQR) for continuous and categorical variables. Comparisons between groups were analyzed using the Mann--Whitney U test for continuous variables and Fisher's exact test for categorical variables. PFS was analyzed using the Kaplan--Meier method, and differences between groups were qualified by log-rank testing. To obtain ORs and hazard ratios (HRs), univariate regressions were performed using logistic and Cox regression, respectively. All reported *p* values are two-tailed, and *p* values \< 0.05 indicate statistical significance. We conducted statistical analyses using R statistical software (R Studio, Inc., <https://www.r-project.org>).

3. Results {#sec3-jcm-09-01959}
==========

3.1. Characteristics of Patients {#sec3dot1-jcm-09-01959}
--------------------------------

### 3.1.1. Before PS Matching {#sec3dot1dot1-jcm-09-01959}

The demographic and clinical characteristics of the progression and improvement/stabilization groups are summarized in [Table 1](#jcm-09-01959-t001){ref-type="table"}. The median age of the 293 patients was 29 years (IQR, 24--47 years), and 214 (73.0%) patients were male. Of the infections, 98.0% were community-associated cases. The most common symptoms at admission were productive cough (83 \[28.3%\]), fever (75 \[25.6%\]), and cough (69 \[23.5%\]), but more patients were asymptomatic (97 \[33.1%\]), and 279 patients were assigned ECOG performance status scores of zero (95.2%).

The median days from the onset of symptoms to disease confirmation was 1 day (IQR, 0--6 days), and that from onset to hospital admission was 6 days (IQR, 0--12 days). The median duration of hospitalization was 18 days (IQR, 15--20 days), and hospitalized patients had a median duration of symptoms of 7 days (IQR, 0--15 days). As of April 4, 2020, 207 (70.6%) of 293 patients had been discharged, and 2 (0.7%) patients had been transferred due to symptom aggravation. The patients' discharge assessments were based on abatement of all symptoms, with two consecutive negative RT-PCR tests for COVID-19.

According to baseline chest CT imaging, 64 (21.8%) patients had findings consistent with bilateral pneumonia, and 56 (19.1%) patients had unilateral pneumonia. Supplementary oxygen was required in 10 patients (3.4%). One hundred patients (34.1%) were administered antibiotics empirically: the treatment regimen was quinolone (84 patients \[28.7%\]) or combination therapy with cefotaxime and doxycycline (14 patients \[4.8%\]). In addition, 30 patients (10.2%) received lopinavir/ritonavir antiviral therapy, although it was withdrawn in 21 of these 30 patients (70.0%) due to side effects such as nausea and vomiting.

Thirty-six (12.3%) cases were classified as the progression group, and the remaining 257 (87.7%) cases were classified as the improvement/stabilization group. The progression group of COVID-19 patients was significantly older than the improvement/stabilization group (49.5 vs. 27.0 years of age; *p* \< 0.001). There were no statistically significant differences between sex and times from symptom onset to confirmation/ admission. The progression group included a greater proportion of cases of healthcare-associated infection than the improvement/stabilization group (*p* = 0.003). A greater proportion of patients in the progression group presented initial symptoms of fever, chest pain, dyspnea, myalgia or fatigue, chills, and diarrhea compared with patients in the improvement/stabilization group, while a greater proportion of patients in the improvement/stabilization group were asymptomatic.

Compared with the improvement/stabilization group, the progression group was more likely to have comorbidities such as hypertension (*p* = 0.003) and diabetes mellitus (*p* \< 0.001). Given the greater incidence of pre-existing conditions, a greater proportion of patients in the progression group had a history of drug use, including ibuprofen (*p* = 0.044), angiotensin II receptor blockers (ARB; *p* = 0.006), calcium channel blockers (CCB; *p* = 0.047), dipeptidyl peptidase-4 inhibitors (DPP4i; *p* \< 0.001), metformin (*p* \< 0.001), and/or statins (*p* = 0.006).

### 3.1.2. After PS Matching {#sec3dot1dot2-jcm-09-01959}

We conducted PS matching to adjust baseline demographics and clinical variables between the progression and improvement/stabilization groups, resulting in 36 matched pairs of patients. Confounding variables were well balanced in the two groups, including all the 10 variables identified above in the Methods section ([Table 2](#jcm-09-01959-t002){ref-type="table"}). After PS matching, prior history of drug use, including ibuprofen, ARB, DPP4i, was not statistically different between patients in the progression and improvement/stabilization groups. Similarly, the effect of these drugs on patient prognosis did not differ significantly in subgroup analysis of patients with hypertension ([Table A2](#jcm-09-01959-t0A2){ref-type="table"}) or diabetes mellitus ([Table A3](#jcm-09-01959-t0A3){ref-type="table"}).

3.2. Comparison of the Predictive Models {#sec3dot2-jcm-09-01959}
----------------------------------------

To confirm that KCDC classifications were suitable for initial triage of patients with COVID-19, the predictive values were compared to those of existing models using receiver operating characteristics analysis. As summarized in [Table 3](#jcm-09-01959-t003){ref-type="table"}, all predictive values were significantly greater in the progression group than in the improvement/stabilization group (*p* \< 0.001). KCDC classification I had the largest area under the curve (AUC, 0.817; 95% CI, 0.740--0.895). After incorporating the CT score measured using baseline chest CT imaging into the KCDC classification I scheme, the AUC was 0.846 (95% CI, 0.768--0.923), improving the predictive power.

3.3. Lopinavir/Ritonavir Treatment Outcomes {#sec3dot3-jcm-09-01959}
-------------------------------------------

Of the 293 patients with COVID-19, 30 were treated with lopinavir/ritonavir ([Table A4](#jcm-09-01959-t0A4){ref-type="table"}). Patients chosen to receive lopinavir/ritonavir treatment were more likely to be in a higher risk group than patients who did not receive lopinavir/ritonavir treatment. After adjusting for confounding variables via PS matching, there were no significant differences between the groups for any of the 10 characteristics identified in the Methods section above. However, even after matching, 18 of 30 (60.0%) patients who received lopinavir/ritonavir treatment showed disease progression, while 6 of 30 (20.0%) patients who did not receive lopinavir/ritonavir treatment experienced disease progression. Patients treated in the lopinavir/ritonavir group had significantly shorter PFS than that in the group not receiving lopinavir/ritonavir both before and after PS matching, but there was no significant difference in the proportion of discharged patients between the two groups ([Figure 2](#jcm-09-01959-f002){ref-type="fig"} and [Table A5](#jcm-09-01959-t0A5){ref-type="table"}).

4. Discussions {#sec4-jcm-09-01959}
==============

In this cohort study, we reported the clinical characteristics of COVID-19 patients and risk factors associated with disease progression, especially those associated with early stages of the disease. We also assessed the usefulness of the KCDC classification for initial patient triage.

There are considerable differences between our study and previous studies of the course and severity of COVID-19. In previous reports addressing Chinese COVID-19 patients, most of the patients were middle-aged and elderly, presented fever and/or cough, and chest CT indicated pneumonia in most patients \[[@B4-jcm-09-01959],[@B6-jcm-09-01959],[@B7-jcm-09-01959],[@B12-jcm-09-01959],[@B13-jcm-09-01959],[@B26-jcm-09-01959],[@B27-jcm-09-01959]\]. In our study, the median age was 29 years, 33.1% of patients were asymptomatic at hospital admission, and pneumonia was evident in chest CT scans in only 41.3% of patients. In South Korea, COVID-19 patients were identified and classified at an early stage through use of large-scale diagnostic testing in accordance with national policy, which allowed both asymptomatic and symptomatic patients to receive inpatient treatment.

The risk factors significantly associated with disease progression were older age, healthcare-associated infection, ECOG performance status, presence of initial symptoms at the time of hospital admission, higher initial PR, lower initial SpO2, hypertension, and diabetes, which were consistent with prior reports \[[@B4-jcm-09-01959],[@B6-jcm-09-01959],[@B12-jcm-09-01959],[@B21-jcm-09-01959],[@B23-jcm-09-01959],[@B28-jcm-09-01959]\]. In contrast, asymptomatic cases at the time of hospital admission had favorable outcomes.

SARS-CoV-2 infects host cells by interacting with the angiotensin-converting enzyme (ACE) 2 receptors \[[@B29-jcm-09-01959]\], which are expressed by epithelial cells in the lung, kidney, intestine, and blood vessels \[[@B30-jcm-09-01959]\]. The high prevalence of ARDS and gastrointestinal symptoms such as diarrhea, nausea, and vomiting can be explained by this ACE-2-receptor-mediated mechanism in COVID-19 patients \[[@B31-jcm-09-01959]\]. ACE inhibitors (ACEi) and ARBs that affect the renin--angiotensin--aldosterone system (RAAS) are commonly recommended for patients with hypertension \[[@B32-jcm-09-01959]\]. In an animal model \[[@B33-jcm-09-01959]\] and human studies \[[@B34-jcm-09-01959],[@B35-jcm-09-01959]\], administration of ACEi and ARBs has been shown to increase the number of ACE2 receptors; ibuprofen and thiazolidinediones may also increase ACE2 expression \[[@B36-jcm-09-01959]\]. Therefore, prior use of these drugs may be a risk factor for SARS-CoV 2 infection. Similar to the ACE2 receptor, human CD26 (also called DPP4) is also suggested as the potential binding site for COVID-19 \[[@B37-jcm-09-01959]\]. Thus, DPP4i, which is widely used as a diabetes drug, may produce effects similar to ARBs in COVID-19 patients. However, given only small-scale clinical studies addressing ACEi/ARB use and patient outcomes in hospital settings \[[@B28-jcm-09-01959]\] have been completed to date, the impact of these drugs on COVID-19 is controversial. Moreover, Vaduganathan et al. suggested that recombinant ACE2 protein may restore balance to the RAAS and potentially prevent organ damage, and drugs acting on ACE2 may benefit rather than harm COVID-19 patients \[[@B38-jcm-09-01959]\]. To analyze the impact of drugs acting on the ACE2 receptor and human CD26 in COVID-19 patients, we conducted a PS matched study. Before matching, the proportion of patients reporting prior use of these drugs was significantly greater in the progression group; however, after adjusting for 10 confounding variables, including underlying comorbidities, there was no significant difference between patients with and without these medication histories. Even after comparing the sums of three (ibuprofen, ARBs, and thiazolidinediones) or four drugs (ibuprofen, ARBs, thiazolidinediones, and DPP4i), no significant differences were found between the two groups. Furthermore, in subgroup analysis of patients with hypertension and diabetes mellitus, the effect of these drugs on patient prognosis was not statistically significant. These results suggest that, in diseases such as hypertension and diabetes mellitus, the underlying pathophysiology associated with the RAAS affects the prognosis of COVID-19 patients rather than the pharmacologic effects of the drugs used to control the disease.

In the global COVID-19 pandemic, the major challenge is the lack of medical resources. We evaluated use of the KCDC classifications to triage patients with COVID-19 according to severity of the disease and to ensure they are treated at the appropriate medical institution. Our results indicated that KCDC classification I had a good AUC (0.817; 95% CI 73.98-89.46) and sensitivity, which suggested that this model is suitable for early screening of low-risk patients who are less likely to progress to severe disease. The use of the triage algorithm and KCDC classification for COVID-19 patients saves medical resources, allowing more efficient treatment and management of patients. Using the KCDC classification as a predictive model in the early stages of COVID-19 outbreaks, more medical resources could be focused on patients with more severe disease, which may have underlain the relatively low CFR in South Korea.

The CT scores (AUC \> 0.7) for the COVID-19 patients in this study clearly distinguished the progression group from the improvement/stabilization group, a finding which is consistent with previous reports \[[@B21-jcm-09-01959],[@B22-jcm-09-01959],[@B23-jcm-09-01959]\]. The use of the KCDC classification I scheme with the CT score increased the AUC and specificity of the predictive model. Therefore, we suggest that triaging patients by applying these predictive models in accordance with the medical conditions and policies of each country may help manage patients in the COVID-19 pandemic situation.

In our clinical study, which comprised mostly mild to moderate cases, patients who received lopinavir/ritonavir treatment were not likely to experience a decrease in PFS; rather, the patients' symptoms may have been aggravated due to side effects of the antivirals. In a previous randomized controlled trial conducted in patients with severe COVID-19, there was no treatment benefit of lopinavir/ritonavir: of 95 patients receiving lopinavir/ritonavir treatment, 48 (48.4%) had gastrointestinal side effects \[[@B39-jcm-09-01959]\], which is consistent with our data.

The retrospective and single-center nature of our study may limit wider applicability of the results. Due to the limited number of cases in the progression group, it was difficult to analyze risk factors for disease progression using multivariable-adjusted methods. Thus, hidden bias and residual confounding factors might have influenced our results. Another limitation of our study was that, to protect medical staff and minimize further spread of the disease in the hospital setting, routine laboratory tests were not conducted in all patients, and these data were not available for inclusion in the analyses. However, we tried to analyze risk factors for disease progression and treatment outcomes for COVID-19 patients while minimizing selection bias using the PS matched study.

After controlling for potential biases using PS matching analysis, drugs acting on the ACE2 receptor and human CD26 were not risk factors for disease progression. We also demonstrated that the KCDC classification I was able to distinguish the improvement/stabilization group from the progression group of COVID-19 patients, and the triage algorithm system saved medical resources, enabling efficient treatment and management of COVID-19 patients in South Korea.
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jcm-09-01959-t0A1_Table A1

###### 

Logistic regression of risk factors for COVID-19 disease progression \*.

                                                       OR     95% CI         *p*
  ---------------------------------------------------- ------ -------------- ---------
  Age                                                  1.07   1.04--1.10     \<0.001
  Male sex                                             0.71   0.33--1.49     0.360
  Healthcare-associated infection                      7.70   1.49--39.71    0.015
  ECOG performance status                              5.68   2.07--15.56    0.001
  Time from disease confirmation to admission, days    0.97   0.86--1.09     0.567
  Time from symptom onset to admission, days           1.02   0.98--1.07     0.312
  Time from symptom onset to confirmation, days        1.03   0.97--1.09     0.322
  Time from admission to discharge, days               0.95   0.87--1.04     0.304
  Symptom duration, days                               1.07   1.04--1.11     0.001
  Initial symptoms                                                           
   Asymptomatic                                        0.16   0.05--0.53     0.003
   Productive cough                                    1.99   0.97--4.07     0.061
   Fever                                               4.59   2.23--9.45     \<0.001
   Cough                                               0.37   0.13--1.08     0.070
   Headache                                            3.77   1.81--7.84     \<0.001
   Myalgia or fatigue                                  2.92   1.39--6.13     0.005
   Chills                                              7.09   3.37--14.93    \<0.001
   Sore throat                                         1.53   0.62--3.76     0.353
   Rhinorrhea                                          0.88   0.29--2.65     0.819
   Dyspnea                                             7.85   3.09--19.93    \<0.001
   Diarrhea                                            4.93   1.80--13.51    0.002
   Nausea or vomiting                                  3.80   0.91--15.93    0.068
   Chest pain                                          6.30   1.61--24.68    0.008
  Initial signs                                                              
   Body temperature, °C                                9.41   3.98--22.25    \<0.001
   Systolic blood pressure, mm Hg                      1.01   0.99--1.03     0.402
   Diastolic blood pressure, mm Hg                     1.03   1.00--1.06     0.048
   Pulse rate, beats/min                               1.04   1.01--1.06     0.010
   Respiratory rate, breaths/min                       1.12   0.94--1.33     0.218
   SpO2, %                                             0.71   0.55--0.91     0.007
  Comorbidities                                                              
   Hypertension                                        3.95   1.64--9.54     0.002
   Diabetes mellitus                                   8.60   3.34--22.17    \<0.001
   Allergic disease                                    0.17   0.02--1.28     0.085
   Chronic lung disease                                1.58   0.43--5.78     0.491
   Peripheral vascular disease                         0.58   0.07--4.63     0.610
   Malignant tumors                                    NA                    
   Liver disease                                       1.81   0.20--16.63    0.601
   Congestive heart failure                            3.72   0.66--21.09    0.138
   Cerebrovascular disease                             4.98   0.80--30.88    0.085
   Rheumatic disease                                   7.31   0.45--119.59   0.163
   Acute myocardial infarction                         NA                    
   Kidney disease                                      NA                    
  Prior history of drug use                                                  
   Ibuprofen                                           3.23   1.16--8.95     0.024
   Angiotensin II receptor blocker                     4.94   1.68--14.56    0.004
   Calcium channel blocker                             3.61   1.18--11.07    0.025
   Beta blocker                                        2.10   0.42--10.53    0.367
   Diuretic                                            NA                    
   Dipeptidyl peptidase-4 inhibitor                    8.89   3.10--25.54    \<0.001
   Metformin                                           8.37   2.54--27.59    0.001
   Sulfonylurea                                        7.50   1.02--1.55     0.048
   Thiazolidinedione                                   NA                    
   Sodium--glucose cotransporter-2 inhibitors          NA                    
   Gabapentinoid                                       NA                    
   Isosorbide                                          NA                    
   Statin                                              4.94   1.68--14.56    0.004
  Number of drugs acting on the ACE2 receptor ^†^      4.37   2.14--8.92     \<0.001
  Number of drugs acting on the ACE2 and/or DDP4 ^‡^   3.66   2.05--6.55     \<0.001
  KCDC classification I                                8.67   4.57--16.45    \<0.001
  KCDC classification II                               2.29   1.59--3.30     \<0.001
  CT score                                             1.22   1.15--1.31     \<0.001
  MuLBSTA                                              1.28   1.16--1.42     \<0.001
  CURB65                                               4.86   1.88--12.57    0.001
  Pneumonia severity index                             2.81   1.76--4.47     \<0.001
  Age--adjusted Charlson comorbidity index             1.73   1.36--2.20     \<0.001

\* OR, odds ratio; CI, confidence interval; NA, not available; ECOG, Eastern Cooperative Oncology Group performance status; SpO2, Pulse Oximeter Oxygen Saturation; KCDC, Korea Centers for Disease Control and Prevention; CT, computed tomography; MuLBSTA, Multilobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension and Age; CURB65, Confusion, Urea, Respiratory rate, Blood pressure plus age ≥ 65 years. ^†^ Includes ibuprofen, angiotensin II receptor blockers, and thiazolidinediones. ^‡^ Includes ibuprofen, angiotensin II receptor blockers, thiazolidinediones, and dipeptidyl peptidase-4 inhibitor.

jcm-09-01959-t0A2_Table A2

###### 

Subgroup analysis of the effect of prior use of drugs in COVID-19 patients with hypertension.

                                    Progression, No. (%)   Improvement/Stabilization, No. (%)   *p*
  --------------------------------- ---------------------- ------------------------------------ ---------
  Age, median (IQR)                 55 (53.0--61.0)        51.5 (48.0--55.5)                    0.125
  Angiotensin II receptor blocker   6 (66.7%)              10 (50.0%)                           0.666
  Calcium channel blocker           5 (55.6%)              11 (55.0%)                           \>0.999
  Ibuprofen                         2 (22.2%)              1 (5.0%)                             0.453
  Beta blocker                      2 (22.2%)              2 (10.0%)                            0.763
  Diuretic                          0 (0.0%)               2 (10.0%)                            0.848

jcm-09-01959-t0A3_Table A3

###### 

Subgroup analysis of the effect of prior use of drugs in COVID-19 patients with diabetes mellitus.

                                             Progression, No. (%)   Improvement/Stabilization, No. (%)   *p*
  ------------------------------------------ ---------------------- ------------------------------------ ---------
  Age, median (IQR)                          52.5 (47.0--55.0)      52.0 (51.0--55.0)                    0.915
  Dipeptidyl peptidase-4 inhibitor           8 (80.0%)              8 (72.7%)                            \>0.999
  Metformin                                  6 (60.0%)              6 (54.5%)                            \>0.999
  Angiotensin II receptor blocker            4 (40.0%)              1 (9.1%)                             0.251
  Ibuprofen                                  1 (10.0%)              1 (9.1%)                             \>0.999
  Thiazolidinedione                          1 (10.0%)              0 (0.0%)                             0.476
  Sulfonylurea                               2 (20.0%)              2 (18.2%)                            \>0.999
  Sodium-glucose cotransporter-2 inhibitor   0 (0.0%)               1 (9.1%)                             \>0.999
  Gabapentinoid                              0 (0.0%)               1 (9.1%)                             \>0.999
  Isosorbide                                 1 (10.0%)              0 (0.0%)                             0.476

jcm-09-01959-t0A4_Table A4

###### 

Lopinavir/ritonavir treatment outcomes in COVID-19 patients before and after propensity-score matching \*.

                                                                    Before Propensity-Score Matching                          After Propensity-Score Matching                                                 
  ----------------------------------------------------------------- ---------------------------------- ---------------------- --------------------------------- ---------------------- ---------------------- ---------
  Disease progression                                               18 (60.0%)                         18 (6.8%)              \<0.001                           18 (60.0%)             6 (20.0%)              0.004
  Age, median (IQR)                                                 54 (47--59)                        27 (23--46)            \<0.001                           54 (47--59)            51 (46--55)            0.230
  Male sex                                                          19 (63.3%)                         195 (74.1%)            0.295                             19 (63.3%)             9 (30.0%)              0.020
  Healthcare-associated infection                                   4 (13.3%)                          2 (0.8%)               \<0.001                           4 (13.3%)              2 (6.7%)               0.667
  ECOG performance status                                                                                                     \<0.001                                                                         0.041
   0                                                                19 (63.3%)                         260 (98.9%)                                              19 (63.3%)             27 (90.0%)             
   1                                                                9 (30.0%)                          3 (1.1%)                                                 9 (30.0%)              3 (10.0%)              
   2                                                                2 (6.7%)                           0 (0.0%)                                                 2 (6.7%)               0 (0.0%)               
  Time from disease confirmation to admission, median (IQR), days   3.5 (3.0--5.0)                     5.0 (3.0--7.0)         0.037                             3.5 (3.0--5.0)         5.0 (3.0--7.0)         0.058
  Time from symptom onset to admission, median (IQR), days          6.0 (4.0--9.0)                     6.0 (0.0--12.0)        0.336                             6.0 (4.0--9.0)         11.0 (8.0--15.0)       0.001
  Time from symptom onset to confirmation, median (IQR), days       3.0 (0.0--5.0)                     1.0 (0.0--6.0)         0.283                             3.0 (0.0--5.0)         5.0 (2.0--9.0)         0.032
  Initial symptoms (may be multiple)                                                                                                                                                                          
   Asymptomatic                                                     0 (0.0%)                           97 (36.9%)             \<0.001                           0 (0.0%)               0 (0.0%)               NA
   Productive cough                                                 12 (40.0%)                         71 (27.0%)             0.199                             12 (40.0%)             18 (60.0%)             0.197
   Fever                                                            18 (60.0%)                         57 (21.7%)             \<0.001                           18 (60.0%)             16 (53.3%)             0.794
   Cough                                                            6 (20.0%)                          63 (24.0%)             0.798                             6 (20.0%)              8 (26.7%)              0.760
   Headache                                                         17 (56.7%)                         44 (16.7%)             \<0.001                           17 (56.7%)             9 (30.0%)              0.068
   Myalgia or fatigue                                               13 (43.3%)                         47 (17.9%)             0.002                             13 (43.3%)             7 (23.3%)              0.171
   Chills                                                           16 (53.3%)                         38 (14.4%)             \<0.001                           16 (53.3%)             10 (33.3%)             0.193
   Sore throat                                                      9 (30.0%)                          33 (12.5%)             0.021                             9 (30.0%)              7 (23.3%)              0.770
   Rhinorrhea                                                       2 (6.7%)                           34 (12.9%)             0.486                             2 (6.7%)               2 (6.7%)               \>0.999
   Dyspnea                                                          11 (36.7%)                         11 (4.2%)              \<0.001                           11 (36.7%)             4 (13.3%)              0.074
   Diarrhea                                                         8 (26.7%)                          11 (4.2%)              \<0.001                           8 (26.7%)              1 (3.3%)               0.030
   Nausea or vomiting                                               4 (13.3%)                          5 (1.9%)               0.004                             4 (13.3%)              1 (3.3%)               0.350
   Chest pain                                                       3 (10.0%)                          6 (2.3%)               0.078                             3 (10.0%)              2 (6.7%)               \>0.999
  Initial signs (may be multiple)                                                                                                                                                                             
   Body temperature, median (IQR), °C                               37.2 (36.5--37.5)                  36.7 (36.5--37.0)      0.010                             37.2 (36.5--37.5)      37.0 (36.6--37.3)      0.784
   Systolic blood pressure, median (IQR), mm Hg                     133.5 (115.0--140.0)               133.0 (122.0--141.0)   0.392                             133.5 (115.0--140.0)   133.5 (123.0--142.0)   0.395
   Diastolic blood pressure, median (IQR), mm Hg                    81.0 (74.0--86.0)                  78.0 (72.0--85.0)      0.379                             81.0 (74.0--86.0)      75.5 (73.0--82.0)      0.411
   Pulse rate, median (IQR), beats/min                              87.0 (77.0--98.0)                  86.0 (75.5--95.5)      0.340                             87.0 (77.0--98.0)      89.0 (80.0--100.0)     0.700
   Respiratory rate, median (IQR), beats/min                        17.0 (16.0--18.0)                  16.0 (16.0--18.0)      0.098                             17.0 (16.0--18.0)      16.0 (16.0--20.0)      0.666
   SpO2, median (IQR), %                                            98.0 (97.0--99.0)                  98.0 (98.0--99.0)      0.031                             98.0 (97.0--99.0)      98.0 (97.0--99.0)      0.284
  Comorbidities (may be multiple)                                                                                             0.000                                                                           0.000
   Hypertension                                                     9 (30.0%)                          20 (7.6%)              \<0.001                           9 (30.0%)              7 (23.3%)              0.770
   Diabetes mellitus                                                8 (26.7%)                          13 (4.9%)              \<0.001                           8 (26.7%)              5 (16.7%)              0.531
   Allergic disease                                                 0 (0.0%)                           38 (14.4%)             0.052                             0 (0.0%)               6 (20.0%)              0.031
   Chronic lung disease                                             2 (6.7%)                           15 (5.7%)              \>0.999                           2 (6.7%)               4 (13.3%)              0.667
   Peripheral vascular disease                                      1 (3.3%)                           12 (4.6%)              \>0.999                           1 (3.3%)               5 (16.7%)              0.197
   Malignant tumors                                                 2 (6.7%)                           5 (1.9%)               0.323                             2 (6.7%)               2 (6.7%)               \>0.999
   Liver disease                                                    0 (0.0%)                           5 (1.9%)               0.986                             0 (0.0%)               0 (0.0%)               NA
   Congestive heart failure                                         3 (10.0%)                          3 (1.1%)               0.010                             3 (10.0%)              0 (0.0%)               0.236
   Cerebrovascular disease                                          1 (3.3%)                           4 (1.5%)               \>0.999                           1 (3.3%)               2 (6.7%)               \>0.999
   Rheumatic disease                                                1 (3.3%)                           1 (0.4%)               0.490                             1 (3.3%)               0 (0.0%)               \>0.999
   Acute myocardial infarction                                      1 (3.3%)                           0 (0.0%)               0.189                             1 (3.3%)               0 (0.0%)               \>0.999
   Kidney disease                                                   0 (0.0%)                           1 (0.4%)               \>0.999                           0 (0.0%)               0 (0.0%)               NA
  Prior history of drug use                                                                                                                                                                                   
   Ibuprofen                                                        6 (20.0%)                          15 (5.7%)              0.012                             6 (20.0%)              6 (20.0%)              \>0.999
   Angiotensin II receptor blocker                                  5 (16.7%)                          11 (4.2%)              0.015                             5 (16.7%)              4 (13.3%)              \>0.999
   Calcium channel blocker                                          6 (20.0%)                          10 (3.8%)              0.001                             6 (20.0%)              2 (6.7%)               0.255
   Beta blocker                                                     3 (10.0%)                          6 (2.3%)               0.078                             3 (10.0%)              1 (3.3%)               0.605
   Diuretic                                                         0 (0.0%)                           2 (0.8%)               \>0.999                           0 (0.0%)               1 (3.3%)               \>0.999
   Dipeptidyl peptidase-4 inhibitor                                 7 (23.3%)                          9 (3.4%)               \<0.001                           7 (23.3%)              5 (16.7%)              0.747
   Metformin                                                        6 (20.0%)                          6 (2.3%)               \<0.001                           6 (20.0%)              3 (10.0%)              0.470
   Sulfonylurea                                                     2 (6.7%)                           2 (0.8%)               0.070                             2 (6.7%)               1 (3.3%)               \>0.999
   Thiazolidinediones                                               0 (0.0%)                           1 (0.4%)               \>0.999                           0 (0.0%)               0 (0.0%)               NA
   Sodium-glucose cotransporter-2 inhibitor                         0 (0.0%)                           1 (0.4%)               \>0.999                           0 (0.0%)               0 (0.0%)               NA
   Gabapentinoid                                                    0 (0.0%)                           1 (0.4%)               \>0.999                           0 (0.0%)               0 (0.0%)               NA
   Isosorbide                                                       1 (3.3%)                           0 (0.0%)               0.189                             1 (3.3%)               0 (0.0%)               \>0.999
   Statin                                                           7 (23.3%)                          9 (3.4%)               \<0.001                           7 (23.3%)              4 (13.3%)              0.505
  Number of drugs acting on the ACE2 receptor ^†^                                                                             \<0.001                                                                         0.577
   0                                                                21 (70.0%)                         245 (93.2%)                                              21 (70.0%)             22 (73.3%)             
   1                                                                6 (20.0%)                          16 (6.1%)                                                6 (20.0%)              7 (23.3%)              
   2                                                                3 (10.0%)                          1 (0.4%)                                                 3 (10.0%)              1 (3.3%)               
   3                                                                0 (0.0%)                           1 (0.4%)                                                 0 (0.0%)               0 (0.0%)               
  Number of drugs acting on the ACE2 receptor and/or DDP4 ^‡^                                                                 \<0.001                                                                         0.706
   0                                                                17 (56.7%)                         232 (88.2%)                                              17 (56.7%)             17 (56.7%)             
   1                                                                9 (30.0%)                          27 (10.3%)                                               9 (30.0%)              11 (36.7%)             
   2                                                                3 (10.0%)                          3 (1.1%)                                                 3 (10.0%)              2 (6.7%)               
   3                                                                1 (3.3%)                           1 (0.4%)                                                 1 (3.3%)               0 (0.0%)               

\* ECOG, Eastern Cooperative Oncology Group performance status; SpO2, Pulse Oximeter Oxygen Saturation; ACE, angiotensin converting enzyme; DDP4, dipeptidyl peptidase 4. ^†^ Includes ibuprofen, angiotensin II receptor blockers, and thiazolidinediones. ^‡^ Includes ibuprofen, angiotensin II receptor blockers, thiazolidinediones, and dipeptidyl peptidase-4 inhibitor.
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###### 

Cox regression of risk factors for progression-free survival of COVID-19 patients \*.

                                                      HR       95% CI         *p*
  --------------------------------------------------- -------- -------------- ---------
  Age                                                 1.061    1.04--1.09     \<0.001
  Male ex                                             0.7284   0.36--1.46     0.370
  Healthcare-acquired infection                       6.214    1.90--20.30    0.002
  ECOG performance status                             3.373    1.89--6.02     \<0.001
  Time from disease confirmation to admission, days   0.9714   0.87--1.09     0.607
  Time from symptom onset to admission, days          1.02     0.98--1.06     0.330
  Time from symptom onset to confirmation, days       1.025    0.97--1.08     0.344
  Initial symptoms                                                            
   Asymptomatic                                       0.169    0.05--0.55     0.003
   Productive cough                                   1.85     0.95--3.59     0.069
   Fever                                              4.139    2.14--7.99     \<0.001
   Cough                                              0.3916   0.14--1.11     0.077
   Headache                                           3.44     1.78--6.64     \<0.001
   Myalgia or fatigue                                 2.704    1.38--5.29     0.004
   Chill                                              5.983    3.11--11.52    \<0.001
   Sore throat                                        1.467    0.64--3.35     0.363
   Rhinorrhea                                         0.8683   0.31--2.46     0.790
   Dyspnea                                            6.065    2.92--12.59    \<0.001
   Diarrhea                                           4.33     1.90--9.90     0.001
   Nausea or vomiting                                 3.423    1.05--11.17    0.041
   Chest pain                                         5.574    1.97--15.79    0.001
  Initial signs                                                               
   Body temperature, °C                               4.033    2.74--5.94     \<0.001
   Systolic blood pressure, mm Hg                     1.01     0.99--1.03     0.402
   Diastolic blood pressure, mm Hg                    1.027    1.00--1.06     0.046
   Pulse rate, beats/min                              1.035    1.01--1.06     0.007
   Respiratory rate, beats/min                        1.106    0.94--1.30     0.217
   SpO2, %                                            0.7119   0.56--0.90     0.005
  Comorbidities                                                               
   Hypertension                                       3.56     1.67--7.58     0.001
   Diabetes mellitus                                  6.59     3.17--13.69    \<0.001
   Allergic disease                                   0.1782   0.02--1.30     0.089
   Chronic lung disease                               1.473    0.45--4.80     0.521
   Peripheral vascular disease                        0.6158   0.084--4.50    0.633
   Cerebrovascular disease                            4.71     1.13--19.62    0.033
   Rheumatic disease                                  4.95     0.68--36.20    0.115
   Congestive heart failure                           3.239    0.78--13.49    0.107
  Prior history of drug use                                                   
   Ibuprofen                                          2.722    1.13--6.54     0.025
   Angiotensin II receptor blocker                    4.261    1.77--10.25    0.001
   Calcium channel blocker                            3.251    1.26--8.37     0.015
   Beta blocker                                       2.056    0.49--8.56     0.322
   Dipeptidyl peptidase-4 inhibitor                   6.878    3.13--15.12    \<0.001
   Metformin                                          6.196    2.58--14.91    \<0.001
   Sulfonylurea                                       5.775    1.39--24.08    0.016
   Thiazolidinedione                                  42.2     5.41--329.10   \<0.001
   Isosorbide                                         17.69    2.35--132.90   0.005
   Statin                                             4.46     1.86--10.73    0.001
  KCDC classification I                               6.172    3.87--9.85     \<0.001
  KCDC classification II                              2.137    1.54--2.97     \<0.001
  CT score                                            1.191    1.13--1.25     \<0.001
  MuLBSTA                                             1.253    1.15--1.37     \<0.001
  CURB65                                              4.142    1.97--8.73     \<0.001
  Pneumonia severity index                            2.539    1.74--3.70     \<0.001
  Age-adjusted Charlson comorbidity index             1.608    1.33--1.94     \<0.001

\* HR, hazard ratio; CI, confidence interval; NA; ECOG, Eastern Cooperative Oncology Group performance status; SpO2, Pulse Oximeter Oxygen Saturation; KCDC, Korea Centers for Disease Control and Prevention; CT, computed tomography; MuLBSTA, Multilobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension and Age; CURB65, Confusion, Urea, Respiratory rate, Blood pressure plus age ≥ 65 year.

![Triage algorithm and KCDC classification criteria for clinical severity of COVID-19 in South Korea. Abbreviations: KCDC, Korea Centers for Disease Control and Prevention; RT-PCR, real-time reverse transcription polymerase chain reaction Figure legend: The Living Treatment Center is a quarantine facility for mild or asymptomatic COVID-19 patients who are unable to self-isolate at home. The patients were checked for vital signs twice a day and immediately transferred to hospitals if their symptoms worsened. If their symptoms resolved, the patient was tested according to the standards for lifting the quarantine. Certain state-run facilities and accommodations are designated as Living Treatment Centers and are supplied with medical staff, medical equipment (pulse oximetry device, thermometer, blood pressure monitor, CPR kit, chest X-ray radiograph, etc.), individual relief kits (underwear, toiletries, face masks, etc.), and hygiene kits (thermometer and medical supplies).](jcm-09-01959-g001){#jcm-09-01959-f001}

![Kaplan--Meier survival analysis of progression-free survival (**A**,**B**) and proportion of patients requiring hospitalization (**C**,**D**) according to lopinavir/ritonavir treatment for patients with COVID-19 before and after propensity-score matching Figure legend: Patients treated with lopinavir/ritonavir group showed significantly lower progression-free survival than the without lopinavir/ritonavir group before and after propensity-score matching. but there was no statistical difference in discharge proportion between the two groups.](jcm-09-01959-g002){#jcm-09-01959-f002}

jcm-09-01959-t001_Table 1

###### 

Baseline characteristics of patients with COVID-19, before propensity-score matching \*.

                                                                               Total, No. (%)         Progression, No. (%)   Improvement/Stabilization, No. (%)   *p*
  ----------------------------------------------------------------- ---------- ---------------------- ---------------------- ------------------------------------ ---------
  Age, median (IQR)                                                            29 (24--47)            49.5 (34--57)          27 (23--46)                          \<0.001
  Male sex                                                                     214 (73.0%)            24 (66.7%)             190 (73.9%)                          0.472
  Healthcare-associated infection                                              6 (2.0%)               3 (8.3%)               3 (1.2%)                             0.027
  ECOG performance status                                                                                                                                         \<0.001
  0                                                                            279 (95.2%)            28 (77.8%)             251 (97.7%)                          
  1                                                                            12 (4.1%)              8 (22.2%)              4 (1.6%)                             
  2                                                                            2 (0.7%)               0 (0.0%)               2 (0.8%)                             
  Time from disease confirmation to admission, median (IQR), days              5.0 (3.0--6.0)         4.0 (3.0--6.0)         5.0 (3.0--6.0)                       0.712
  Time from symptom onset to admission, median (IQR), days                     6.0 (0.0--12.0)        8.0 (3.0--10.5)        5.0 (0.0--12.0)                      0.156
  Time from symptom onset to confirmation, median (IQR), days                  1.0 (0.0--6.0)         3.0 (0.0--6.0)         1.0 (0.0--5.0)                       0.198
  Time from admission to discharge, median (IQR), days                         18.0 (15.0--20.0)      18.0 (14.0--20.0)      18.0 (15.5--21.0)                    0.568
  Symptom duration, median (IQR), days                                         7.0 (0.0--15.0)        12.0 (10.0--20.0)      6.0 (0.0--15.0)                      \<0.001
  Initial symptoms (may be multiple)                                                                                                                              
  Asymptomatic                                                                 97 (33.1%)             3 (8.3%)               94 (36.6%)                           0.001
  Productive cough                                                             83 (28.3%)             15 (41.7%)             68 (26.5%)                           0.089
  Fever                                                                        75 (25.6%)             20 (55.6%)             55 (21.4%)                           \<0.001
  Cough                                                                        69 (23.5%)             4 (11.1%)              65 (25.3%)                           0.095
  Headache                                                                     61 (20.8%)             16 (44.4%)             45 (17.5%)                           \<0.001
  Myalgia or fatigue                                                           60 (20.5%)             14 (38.9%)             46 (17.9%)                           0.007
  Chills                                                                       54 (18.4%)             19 (52.8%)             35 (13.6%)                           \<0.001
  Sore throat                                                                  42 (14.3%)             7 (19.4%)              35 (13.6%)                           0.496
  Rhinorrhea                                                                   36 (12.3%)             4 (11.1%)              32 (12.5%)                           \>0.999
  Dyspnea                                                                      22 (7.5%)              10 (27.8%)             12 (4.7%)                            \<0.001
  Diarrhea                                                                     19 (6.5%)              7 (19.4%)              12 (4.7%)                            0.003
  Nausea or vomiting                                                           9 (3.1%)               3 (8.3%)               6 (2.3%)                             0.150
  Chest pain                                                                   9 (3.1%)               4 (11.1%)              5 (1.9%)                             0.014
  Other                                                                        8 (2.7%)               1 (2.8%)               7 (2.7%)                             \>0.999
  Initial signs (may be multiple)                                                                                                                                 
  Body temperature, median (IQR), °C                                           36.7 (36.5--37.0)      37.3 (36.5--37.7)      36.7 (36.5--37.0)                    \<0.001
  Systolic blood pressure, median (IQR), mm Hg                                 133.0 (121.0--141.0)   135.5 (121.5--146.0)   132.0 (121.0--141.0)                 0.335
  Diastolic blood pressure, median (IQR), mm Hg                                79.0 (72.0--85.0)      82.0 (75.5--90.5)      78.0 (72.0--84.0)                    0.015
  Pulse rate, median (IQR), beats/min                                          86.0 (76.0--96.0)      90.0 (79.0--102.5)     85.0 (75.0--95.0)                    0.010
  Respiratory rate, median (IQR), breaths/min                                  16.0 (16.0--18.0)      16.0 (16.0--18.0)      16.0 (16.0--18.0)                    0.105
  SpO2, median (IQR), %                                                        98.0 (98.0--99.0)      98.0 (97.0--99.0)      98.0 (98.0--99.0)                    0.023
  Comorbidities (may be multiple)                                                                                                                                 
  Hypertension                                                                 29 (9.9%)              9 (25.0%)              20 (7.8%)                            0.003
  Diabetes mellitus                                                            21 (7.2%)              10 (27.8%)             11 (4.3%)                            \<0.001
  Allergic disease                                                             38 (13.0%)             1 (2.8%)               37 (14.4%)                           0.093
  Chronic lung disease                                                         17 (5.8%)              3 (8.3%)               14 (5.4%)                            0.754
  Peripheral vascular disease                                                  13 (4.4%)              1 (2.8%)               12 (4.7%)                            0.933
  Malignant tumor(s)                                                           7 (2.4%)               0 (0.0%)               7 (2.7%)                             0.675
  Liver disease                                                                5 (1.7%)               1 (2.8%)               4 (1.6%)                             \>0.999
  Congestive heart failure                                                     6 (2.0%)               2 (5.6%)               4 (1.6%)                             0.338
  Cerebrovascular disease                                                      5 (1.7%)               2 (5.6%)               3 (1.2%)                             0.224
  Rheumatic disease                                                            2 (0.7%)               1 (2.8%)               1 (0.4%)                             0.583
  Acute myocardial infarction                                                  1 (0.3%)               0 (0.0%)               1 (0.4%)                             \>0.999
  Kidney disease                                                               1 (0.3%)               0 (0.0%)               1 (0.4%)                             \>0.999
  Prior history of drug use                                                                                                                                       
  Ibuprofen                                                                    21 (7.2%)              6 (16.7%)              15 (5.8%)                            0.044
  Angiotensin II receptor blockers                                             16 (5.5%)              6 (16.7%)              10 (3.9%)                            0.006
  Calcium channel blocker                                                      16 (5.5%)              5 (13.9%)              11 (4.3%)                            0.047
  Beta blocker                                                                 9 (3.1%)               2 (5.6%)               7 (2.7%)                             0.684
  Diuretics                                                                    2 (0.7%)               0 (0.0%)               2 (0.8%)                             \>0.999
  Dipeptidyl peptidase-4 inhibitor                                             16 (5.5%)              8 (22.2%)              8 (3.1%)                             \<0.001
  Metformin                                                                    12 (4.1%)              6 (16.7%)              6 (2.3%)                             \<0.001
  Sulfonylurea                                                                 4 (1.4%)               2 (5.6%)               2 (0.8%)                             0.122
  Thiazolidinedione                                                            1 (0.3%)               1 (2.8%)               0 (0.0%)                             0.250
  Sodium-glucose cotransporter-2 inhibitor                                     1 (0.3%)               0 (0.0%)               1 (0.4%)                             \>0.999
  Gabapentinoid                                                                1 (0.3%)               0 (0.0%)               1 (0.4%)                             \>0.999
  Isosorbide                                                                   1 (0.3%)               1 (2.8%)               0 (0.0%)                             0.250
  Statin                                                                       16 (5.5%)              6 (16.7%)              10 (3.9%)                            0.006
  Number of drugs acting on the ACE2 receptor ^†^                                                                                                                 \<0.001
  0                                                                            266 (90.8%)            26 (72.2%)             240 (93.4%)                          
  1                                                                            22 (7.5%)              6 (16.7%)              16 (6.2%)                            
  2                                                                            4 (1.4%)               3 (8.3%)               1 (0.4%)                             
  3                                                                            1 (0.3%)               1 (2.8%)               0 (0.0%)                             
  Number of drugs acting on the ACE2 and/or DDP4 ^‡^                                                                                                              \<0.001
  0                                                                            249 (85.0%)            22 (61.1%)             227 (88.3%)                          
  1                                                                            36 (12.3%)             9 (25.0%)              27 (10.5%)                           
  2                                                                            6 (2.0%)               3 (8.3%)               3 (1.2%)                             
  3                                                                            2 (0.7%)               2 (5.6%)               0 (0.0%)                             
  **Available laboratory findings, median (IQR)**                                                                                                                 
  WBC count (10^9^/L)                                               *n* = 26   6.3 (5.1--8.5)         6.0 (5.2--7.7)         8.5 (5.8--9.0)                       0.364
  Hemoglobin (g/dL)                                                 *n* = 26   13.9 (12.6--14.9)      14.0 (12.9--14.9)      13.7 (11.8--15.1)                    0.644
  Platelet count (10^9^/L)                                          *n* = 26   198.5 (156.0--295.0)   171.0 (142.5--287.0)   255.0 (215.5--281.0)                 0.140
  Neutrophil count (10^9^/L)                                        *n* = 26   4.6 (3.0--6.3)         4.6 (3.2--5.3)         6.0 (3.4--6.8)                       0.885
  Lymphocyte count (10^9^/L)                                        *n* = 26   1.4 (1.1--1.7)         1.4 (1.0--1.7)         1.5 (1.3--2.1)                       0.364
  Monocyte count (10^9^/L)                                          *n* = 26   0.4 (0.3--0.7)         0.4 (0.3--0.7)         0.6 (0.3--0.6)                       0.729
  Eosinophil count (10^9^/L)                                        *n* = 26   0.7 (0.0--0.9)         0.3 (0.0--0.8)         1.1 (0.8--1.8)                       0.004
  Activated partial thromboplastin time (sec)                       *n* = 21   28.8 (27.5--32.2)      30.0 (28.1--33.1)      27.5 (27.1--27.6)                    0.099
  Prothrombin time (sec)                                            *n* = 21   10.6 (10.2--11.3)      10.8 (10.4--11.4)      10.2 (9.7--10.4)                     0.089
  BU*N* (mg/dl)                                                     *n* = 26   10.8 (9.7--14.6)       11.2 (10.1--14.5)      10.2 (8.6--12.8)                     0.544
  Serum creatinine (ng/mL)                                          *n* = 26   0.9 (0.7--1.0)         1.0 (0.8--1.1)         0.7 (0.6--0.9)                       0.056
  Total protein (g/dL)                                              *n* = 26   6.9 (6.5--7.6)         6.8 (6.3--7.3)         7.5 (6.8--7.8)                       0.165
  Albumin (g/dL)                                                    *n* = 26   4.0 (3.7--4.2)         3.8 (3.4--4.1)         4.2 (4.0--4.4)                       0.081
  AST (IU/L)                                                        *n* = 26   29.5 (23.0--69.0)      30.0 (25.5--77.0)      24.0 (21.0--38.0)                    0.148
  ALT (IU/L)                                                        *n* = 26   27.5 (17.0--52.0)      30.0 (20.5--60.5)      17.0 (17.0--43.0)                    0.469
  Alkaline phosphatase (IU/L)                                       *n* = 26   75.0 (64.0--94.0)      78.0 (69.0--94.0)      67.0 (63.5--84.5)                    0.563
  CRP (mg/L)                                                        *n* = 26   3.8 (0.5--6.5)         4.8 (1.5--7.7)         0.5 (0.5--2.3)                       0.081

\* IQR, interquartile range, ECOG, Eastern Cooperative Oncology Group performance status; SpO2, pulse oximeter oxygen saturation; ACE, angiotensin converting enzyme; DDP4, dipeptidyl peptidase 4; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, C-reactive protein. ^†^ Includes nonsteroidal anti-inflammatory drug, angiotensin II receptor blockers, and thiazolidinediones. ^‡^ Includes nonsteroidal anti-inflammatory drug, angiotensin II receptor blockers, thiazolidinediones, and dipeptidyl peptidase-4 inhibitors.
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###### 

Baseline characteristics of patients with COVID-19, after propensity-score matching \*.

                                                                    Progression, No. (%)   Improvement/Stabilization, No. (%)   *p*
  ----------------------------------------------------------------- ---------------------- ------------------------------------ ---------
  Age, median (IQR)                                                 49.5 (34.0--57.0)      45.5 (27.5--54.5)                    0.185
  Male sex                                                          24 (66.7%)             19 (52.8%)                           0.336
  Healthcare-associated infection                                   3 (8.3%)               2 (5.6%)                             \>0.999
  ECOG performance status                                                                                                       0.109
   0                                                                28 (77.8%)             31 (86.1%)                           
   1                                                                8 (22.2%)              3 (8.3%)                             
   2                                                                0 (0.0%)               2 (5.6%)                             
  Time from disease confirmation to admission, median (IQR), days   4.0 (3.0--6.0)         5.0 (3.0--8.0)                       0.222
  Time from symptom onset to admission, median (IQR), days          8.0 (3.0--10.5)        10.0 (5.0--14.0)                     0.194
  Time from symptom onset to confirmation, median (IQR), days       3.0 (0.0--6.0)         3.0 (0.5--8.0)                       0.740
  Initial symptoms (may be multiple)                                                                                            
   Asymptomatic                                                     3 (8.3%)               3 (8.3%)                             \>0.999
   Productive cough                                                 15 (41.7%)             14 (38.9%)                           \>0.999
   Fever                                                            20 (55.6%)             13 (36.1%)                           0.156
   Cough                                                            4 (11.1%)              9 (25.0%)                            0.220
   Headache                                                         16 (44.4%)             10 (27.8%)                           0.220
   Myalgia or fatigue                                               14 (38.9%)             12 (33.3%)                           0.806
   Chills                                                           19 (52.8%)             9 (25.0%)                            0.030
   Sore throat                                                      7 (19.4%)              10 (27.8%)                           0.579
   Rhinorrhea                                                       4 (11.1%)              6 (16.7%)                            0.733
   Dyspnea                                                          10 (27.8%)             4 (11.1%)                            0.137
   Diarrhea                                                         7 (19.4%)              3 (8.3%)                             0.307
   Nausea or vomiting                                               3 (8.3%)               3 (8.3%)                             \>0.999
   Chest pain                                                       4 (11.1%)              1 (2.8%)                             0.354
  Initial signs (may be multiple)                                                                                               
   Body temperature, median (IQR), °C                               37.3 (36.5--37.7)      37.1 (36.9--37.3)                    0.443
   Systolic blood pressure, median (IQR), mm Hg                     135.5 (121.5--146.0)   136.5 (125.5--142.0)                 0.897
   Diastolic blood pressure, median (IQR), mm Hg                    82.0 (75.5--90.5)      82.5 (74.0--89.0)                    0.778
   Pulse rate, median (IQR), beats/min                              90.0 (79.0--102.5)     88.0 (82.0--97.5)                    0.389
   Respiratory rate, median (IQR), beats/min                        16.0 (16.0--18.0)      16.0 (16.0--17.0)                    0.108
   SpO2, median (IQR), %                                            98.0 (97.0--99.0)      98.0 (98.0--99.0)                    0.438
  Comorbidities (may be multiple)                                                                                               
   Hypertension                                                     9 (25.0%)              8 (22.2%)                            \>0.999
   Diabetes mellitus                                                10 (27.8%)             6 (16.7%)                            0.395
   Allergic diseases                                                1 (2.8%)               3 (8.3%)                             0.607
   Chronic lung disease                                             3 (8.3%)               3 (8.3%)                             \>0.999
   Peripheral vascular disease                                      1 (2.8%)               5 (13.9%)                            0.201
   Malignant tumor(s)                                               0 (0.0%)               0 (0.0%)                             NA
   Liver disease                                                    1 (2.8%)               1 (2.8%)                             \>0.999
   Cerebrovascular disease                                          2 (5.6%)               1 (2.8%)                             \>0.999
   Rheumatic disease                                                1 (2.8%)               0 (0.0%)                             \>0.999
   Acute myocardial infarction                                      0 (0.0%)               0 (0.0%)                             NA
   Congestive heart failure                                         2 (5.6%)               0 (0.0%)                             0.473
   Kidney disease                                                   0 (0.0%)               0 (0.0%)                             NA
  Prior history of drug use                                                                                                     
   Ibuprofen                                                        6 (16.7%)              2 (5.6%)                             0.261
   Angiotensin II receptor blockers                                 6 (16.7%)              4 (11.1%)                            0.733
   Calcium channel blocker                                          5 (13.9%)              4 (11.1%)                            \>0.999
   Beta blocker                                                     2 (5.6%)               2 (5.6%)                             \>0.999
   Diuretic                                                         0 (0.0%)               1 (2.8%)                             \>0.999
   Dipeptidyl peptidase-4 inhibitor                                 8 (22.2%)              5 (13.9%)                            0.540
   Metformin                                                        6 (16.7%)              3 (8.3%)                             0.476
   Sulfonylurea                                                     2 (5.6%)               1 (2.8%)                             \>0.999
   Thiazolidinedione                                                1 (2.8%)               0 (0.0%)                             \>0.999
   SGLT2 inhibitor                                                  0 (0.0%)               0 (0.0%)                             NA
   Gabapentinoid                                                    30 (83.3%)             32 (88.9%)                           \>0.999
   Isosorbide                                                       1 (2.8%)               0 (0.0%)                             \>0.999
   Statin                                                           6 (16.7%)              3 (8.3%)                             0.476
  Number of drugs acting on the ACE2 receptor ^†^                                                                               0.542
   0                                                                26 (72.2%)             28 (77.8%)                           
   1                                                                6 (16.7%)              7 (19.4%)                            
   2                                                                3 (8.3%)               1 (2.8%)                             
   3                                                                1 (2.8%)               0 (0.0%)                             
  Number of drugs acting on the ACE2 and/or DDP4 ^‡^                                                                            0.343
   0                                                                22 (61.1%)             26 (72.2%)                           
   1                                                                9 (25.0%)              9 (25.0%)                            
   2                                                                3 (8.3%)               1 (2.8%)                             
   3                                                                2 (5.6%)               0 (0.0%)                             

\* IQR, interquartile range, ECOG, Eastern Cooperative Oncology Group performance status; SpO2, Pulse Oximeter Oxygen Saturation; ACE, angiotensin converting enzyme; DDP4, dipeptidyl peptidase 4. ^†^ Includes ibuprofen, angiotensin II receptor blockers, and thiazolidinediones. ^‡^ Includes ibuprofen, angiotensin II receptor blockers, thiazolidinediones, and dipeptidyl peptidase-4 inhibitors.
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###### 

Predictive models for disease severity and progression of patients with COVID-19 \*.

                                                          Total, No. (%)   Progression, No. (%)   Improvement/Stabilization, No. (%)   *p*                                         
  ------------------------------------------------------- ---------------- ---------------------- ------------------------------------ --------- ------- ---------------- -------- --------
  KCDC classification I                                                                                                                \<0.001   0.817   (0.740--0.895)   83.30%   67.70%
   Class I                                                180 (61.4%)      6 (16.7%)              174 (67.7%)                                                                      
   Class II                                               91 (31.1%)       14 (38.9%)             77 (30.0%)                                                                       
   Class III                                              22 (7.5%)        16 (44.4%)             6 (2.3%)                                                                         
  KCDC classification II                                                                                                               \<0.001   0.676   (0.590--0.762)   52.80%   82.50%
   Class I                                                229 (78.2%)      17 (47.2%)             212 (82.5%)                                                                      
   Class III                                              64 (21.8%)       19 (52.8%)             45 (17.5%)                                                                       
  CT score, median (IQR)                                  0.0 (0.0--4.0)   6.2 (1.0--14.5)        0.0 (0.0--3.0)                       \<0.001   0.768   (0.680--0.856)   77.80%   65.00%
  MuLBSTA, median (IQR)                                   0.0 (0.0--5.0)   5.0 (5.0--7.0)         0.0 (0.0--5.0)                       \<0.001   0.744   (0.662--0.825)   77.80%   63.80%
  CURB65                                                                                                                               \<0.001   0.575   (0.507--0.642)   19.40%   95.30%
   0                                                      274 (93.5%)      29 (80.6%)             245 (95.3%)                                                                      
   1                                                      18 (6.1%)        6 (16.7%)              12 (4.7%)                                                                        
   2                                                      1 (0.3%)         1 (2.8%)               0 (0.0%)                                                                         
  Pneumonia severity index                                                                                                             \<0.001   0.659   (0.568--0.750)   50.00%   79.00%
   Class I                                                221 (75.4%)      18 (50.0%)             203 (79.0%)                                                                      
   Class II                                               53 (18.1%)       10 (27.8%)             43 (16.7%)                                                                       
   Class III                                              17 (5.8%)        6 (16.7%)              11 (4.3%)                                                                        
   Class IV                                               2 (0.7%)         2 (5.6%)               0 (0.0%)                                                                         
  Age-adjusted Charlson comorbidity index, median (IQR)   0.0 (0.0--1.0)   1.0 (0.5--4.0)         0.0 (0.0--1.0)                       \<0.001   0.703   (0.610--0.795)   75.00%   56.80%

\* AUC, area under the curve; CI, confidence interval; KCDC, Korea Centers for Disease Control and Prevention; CT, computed tomography, IQR, interquartile range; MuLBSTA, Multilobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension and Age; CURB65, Confusion, Urea, Respiratory rate, Blood pressure plus age ≥ 65 years.

[^1]: These authors contributed equally to this study.
